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68Ga–Prostate-Specific Membrane Antigen Uptake
in a Malignant Pleural Effusion From Metastatic Prostate
Cancer After Pleurodesis
Christos Sachpekidis, MD, Ian Alberts, MBBS, Axel Rominger, MD, and Ali Afshar-Oromieh, MD
Abstract:A 76-year-old man with metastatic adenocarcinoma of the prostate
presented with increasing dyspnea. After being treated initially with drainage
and afterwards with pleurodesis, he was referred for 68Ga–prostate-specific
membrane antigen 11 PET/CT imaging for restaging purposes. PET/CT dem-
onstrated extensive 68Ga–prostate-specific membrane antigen 11 uptake in the
right pleura. Histopathology confirmed the rare case of malignant pleural ef-
fusion from metastatic prostate cancer.
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FIGURE 1. A 76-year-old patient with a history of metastatic
adenocarcinoma of the prostate (Gleason score 9) initially
treated with radical prostatectomy, lymphadenectomy,
and local irradiation presented with increasing dyspnea.
At the time of admission, he was under androgen deprivation
therapy with goserelin, and his plasma PSA level was
24.7 ng/mL. CT revealed a marked pleural effusion, which
was initially treatedwith drainage. Afterward, he underwent
pleural biopsy and pleurodesis via thoracoscopy. For
restaging purposes, the patient was examined with
68Ga–prostate-specific membrane antigen 11 (PSMA-11)
PET/CT. The scans showed a diffuse, intensive tracer
accumulation in the pleura, aswell asmultiple retroperitoneal,
mediastinal, and supraclavicular PSMA-avid lymph node
metastases as well as an osseous metastasis in the 12th
thoracic vertebra. Histopathologic results from the pleura
revealed malignant effusion from metastatic prostate
adenocarcinoma. Prostate cancer most frequently
metastasizes to regional lymph nodes and bones. Pulmonary
metastases appear with a low incidence.1 Moreover, pleural
malignant effusions represent a very rare manifestation of
the disease2; therefore, the gathered experience concerning
pleural metastases depicted with PSMA-ligand PET is
necessarily limited. The role of pleurodesis in the pleural
PSMA-ligand uptake in this patient cannot be determined.
Although the main indication of PSMA-ligand PET/CT lies in
the assessment of prostate cancer in the biochemical relapse
setting, themodality is increasingly gaining importance also
in the initial staging of the intermediate- and high-risk
disease as well as in the restaging of metastatic disease.3–7
It is estimated that PSMA-ligand PET/CT can dictate a
change in therapeutic management of up to 54% of
prostate cancer patients.8 The patient presented here
showed disease progression under goserelin with pleural,
lymph node, and osseous metastases depicted on PET/CT.
As a consequence, his treatment was stopped and was
changed to enzalutamide.
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